Day 2Drug-eluting stentsPharmacology

SOLACI CACI 2017 | BRS at the crossroad: technological development to reduce complications

solaci
solaci
580
0
Dr. Patrick Serruys
Dr. Patrick Serruys

Read articles on the main presentations of the second day of SOLACI-CACI 2017 Congress.

See the presentation by Dr. Patrick Serruys, entitled “BRS at the crossroad: technological development to reduce complications”.

3Serruys-PatrickBRS

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

Previous article
SOLACI CACI 2017 | Present and Future Transcatheter Management of Mitral Insufficiency
Next article
SOLACI CACI | TAVI: Evidencia para pacientes de riesgo intermedio
solaci
solaci

More articles by this author

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

Dr. Andrés Rodríguez - 0
In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

Dr. Andrés Rodríguez - 0
This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

Dr. Andrés Rodríguez - 0
This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

Dr. Andrés Rodríguez - 0
This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Acute coronary syndromes

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current...
Dr. Andrés Rodríguez -
SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Dr. Juan Manuel Pérez - 0
Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

Dr. Andrés Rodríguez - 0
After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

Dr. Andrés Rodríguez - 0
In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...